市場調查報告書
商品編碼
1292426
微生物檢測市場 - 按產品、按檢測類型、按應用、按最終用途及預測,2023 - 2032年Microbiology Testing Market - By Product, By Test Type, By Application, By End-use & Forecast, 2023 - 2032 |
全球微生物學檢測市場規模將在2023-2032年觀察到可觀的成長。對傳染病如COVID-19、流感和其他疾病的認知不斷提高,增加了對微生物檢測的需求,以便早期發現疾病。全球各地的許多政府正在對診斷程序進行大量投資,以防止這些疾病的傳播。此外,在這一領域經營的行業參與者正在創新新產品,以擴大他們的全球足跡,這將有助於在未來十年內改變市場動態。
整個微生物學檢測市場根據產品、檢測、應用、終端用途和地區來分類。
n、最終用途和地區分類。
就類型而言,到2032年,來自病毒部分的行業價值將錄得顯著收益。最近微生物學檢測技術的進步已經改變了病毒性疾病的診斷。現代微生物檢測技術,如聚合酶鍊式反應(PCR)和下一代測序(NGS),已經大大增強了病毒檢測的靈敏度和特異性。這些方法甚至可以檢測到微量的病毒遺傳物質,從而能夠在早期階段識別病毒感染。
基於應用,到2032年,來自胃腸道疾病領域的微生物檢測市場規模將大幅擴大。胃腸道疾病患病率的上升增加了對微生物學檢測的需求。此外,新的創新,如微生物測試的下一代測序,推進了胃腸道問題的診斷。它提供了胃腸道微生物組的全面視圖,並能檢測已知和新型病原體,有助於診斷和了解胃腸道疾病。
基於終端用途,診斷中心部分的微生物檢測市場價值將在2032年之前積累相當大的收益。熟練和有經驗的醫療保健專業人員的高可用性,增加了診斷中心的病人數量。此外,對傳染病認知的提高也增加了對這些設施的需求,進一步促進了該領域的擴張。許多診斷中心與醫療機構合作。
從區域角度看,歐洲微生物檢測市場佔有率將在2023年至2032年以顯著的複合年成長率成長。慢性疾病發病率的成長提高了該地區對微生物學檢測的認知。此外,歐洲也是F. Hoffmann-La Roche Ltd、Merck KGaA等行業領先企業的所在地,它們不斷關注產品創新。事實上,在2021年12月,羅氏公佈了基於cobas(R)5800系統的傳染病測試,這是一種新的分子實驗室設備。
Global Microbiology Testing Market size will observe an appreciable growth over 2023-2032. Growing awareness about infectious diseases such as COVID-19, influenza, and others has increased the need for microbiology testing for early detection of the disease. Many governments across the globe are investing considerable amounts into diagnostic procedures for preventing the spread of these diseases. Moreover, industry players operating in this field are innovating new products to extend their global footprint, which will help transform market dynamics over the next ten years.
The overall microbiology testing market is divided based on product, test, applicatio
n, end-use, and region.
In terms of type, the industry value from the viral segment will register significant gains through 2032. Recent advancements in microbiology testing techniques have transformed the diagnosis of viral disorders. Modern microbiology testing techniques, such as Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), have significantly enhanced the sensitivity and specificity of viral detection. These methods can detect even trace amounts of viral genetic material, enabling the identification of viral infections in the early stages.
Based on application, the microbiology testing market size from the gastrointestinal diseases segment will expand substantially through 2032. Rising prevalence of gastrointestinal diseases has increased the need for microbiology testing. Moreover, novel innovations, such as next-generation sequencing in microbiology testing, have advanced the diagnosis of gastrointestinal issues. It provides a comprehensive view of the gastrointestinal microbiome and enables the detection of both known and novel pathogens, aiding in the diagnosis and understanding of gastrointestinal disorders.
Based on end-use, microbiology testing market value from the diagnostic centers segment will amass considerable gains through 2032. High availability of skilled and experienced healthcare professionals has increased patient footfall in diagnostic centers. Moreover, increasing awareness about infectious diseases has increased the demand for these facilities, further contributing to segment expansion. Many diagnostic centers work in collaboration with healthcare providers.
From the regional perspective, Europe microbiology testing market share will grow at a notable CAGR from 2023 to 2032. Growing prevalence of chronic disorders has increased awareness about microbiology testing in the region. Moreover, Europe is also home to leading industry players such as F. Hoffmann-La Roche Ltd, Merck KGaA, and others focusing on product innovations constantly. In fact, in December 2021, Roche unveiled the launch of infectious disease tests based on the cobas® 5800 System, which is a new molecular laboratory device.